A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Summary

This is an open label, multi-center, Phase II study of BBI503 administered to adult patients with selected advanced urologic malignancies. The primary objective of this study is to evaluate the disease control rate of patients with renal cell cancer and urothelial carcinoma treated with BBI503.

Timeline

Start

2017-01

Primary completion

2018-08-01

Completion

2018-08-01

Outcome

Outcome not reported

Stopped: “Low feasibility”

Drugs

Indications